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The ability of self-replicating RNA (replicon) vaccine vectors derived from the Australian flavivirus Kunjin
(KUN) to induce protective  CD8 T-cell responses was examined. KUN replicons encoding a model
immunogen were delivered by three different vaccine modalities: (i) as naked RNA transcribed in vitro, (ii) as
plasmid DNA constructed to allow in vivo transcription of replicon RNA by cellular RNA polymerase II (DNA
based), and (iii) as replicon RNA encapsidated into virus-like particles. A single immunization with any of
these KUN replicon vaccines induced CD8 T-cell responses at levels comparable to those induced by
recombinant vaccinia virus encoding the same immunogen. Immunization with only 0.1 g of DNA-based KUN
replicons elicited CD8 T-cell responses similar to those seen after immunization with 100 g of a conven-
tional DNA vaccine. Naked RNA immunization with KUN replicons also protected mice against challenges with
recombinant vaccinia virus and B16 tumor cells. These results demonstrate the value of KUN replicon vectors
for inducing protective antiviral and anticancer CD8 T-cell responses.
Replicon-based vectors of positive-strand RNA viruses are
becoming more and more popular for development of antiviral
and anticancer vaccines (reviewed in reference 24). Several
features make these vectors a desirable choice for develop-
ment of highly efficient and safe vaccines. These include (i) a
high level of expression of encoded heterologous genes (HGs)
due to the ability of replicon RNA to amplify itself; (ii) exclu-
sively cytoplasmic replication, which eliminates any possible
complications associated with nuclear splicing and/or chromo-
somal integration; (iii) inability of the replicon RNA to escape
from the transfected (or infected) cell, thus limiting the spread
of the vaccine vector in the immunized subject, which makes
these vectors biologically safe; and (iv) relatively small genome
size (7 to 9 kb), allowing easy manipulations with the cDNA
and generation of recombinants. An additional beneficial fea-
ture of replicon vectors is a variety of modalities that can be
used to deliver replicon RNA into cells (Fig. 1A) (24). It can be
either delivered directly as naked RNA transcribed in vitro
(RNA based), packaged first into virus-like particles (VLPs)
and then delivered via infection with these VLPs, or delivered
in the form of plasmid DNA, which encodes replicon cDNA
placed under the control of a mammalian expression promoter
(DNA based), allowing the production of functional replicon
RNA in vivo by the cellular RNA polymerase II (Fig. 1A).
Replicon-based expression vectors have been developed for
representatives of most positive-strand RNA virus families,
including alphaviruses, picornaviruses, and flaviviruses (re-
viewed in reference 24). However, the great majority of the
data on immunogenic properties of replicon vectors in labora-
tory animals have been accumulated using replicons of alpha-
viruses such as Sindbis virus (SIN), Semliki Forest virus (SFV),
and Venezuelan equine encephalitis virus (VEE) (see refer-
ence 47 for a review and references 8, 10, 11, and 39 for more
recent studies). In general, these studies showed that alphavi-
rus replicon vectors induced strong antibody and CD8 T-cell
responses to encoded immunogens and in most cases protected
immunized animals from appropriate virus or tumor chal-
lenges. All three delivery modalities were effective; however,
VLP delivery was shown to be the most efficient. In compara-
tive studies of conventional (nonreplicating) plasmid DNA
vectors and alphavirus DNA-based replicon vectors, the latter
generally induced stronger immune responses and at signifi-
cantly lower DNA concentrations than did conventional vec-
tors (4, 17). However, in some studies the efficiency of immune
responses induced by DNA-based alphavirus replicons ap-
peared to depend on the nature of the encoded immunogen,
and the immunity to some immunogens was shown to be sim-
ilar to or lower than that induced by the same amount of
conventional plasmid DNA vector (10, 22).
We have been developing replicon vectors derived from the
flavivirus Kunjin (KUN) (25, 27, 52, 53). The KUN replicon
expression system, like alphavirus replicon systems, allows de-
livery of replicon RNA by three different modalities, i.e., as
naked RNA, as VLPs, and as plasmid DNA (Fig. 1A) (24, 52,
53). Unlike homologous alphavirus replicon packaging systems
(6, 33, 41), the KUN replicon packaging system makes use of
a replicon expression vector derived from the unrelated SFV
for production of KUN structural proteins (27, 52). This elim-
inates any potential problems associated with contamination of
VLPs with infectious recombinant material. Additionally, in
contrast to highly cytopathic alphavirus replicon vectors com-
monly used in immunization studies, KUN replicons appear to
be noncytopathic and allow prolonged expression of HGs both
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in vitro and in vivo (53). Although noncytopathic alphavirus
replicon vectors have been developed (1, 12, 40), no data on
their immunogenic properties have been reported. In our pre-
vious studies we demonstrated that immunizations of mice
with a noncytopathic DNA-based KUN replicon vector ex-
pressing the -galactosidase gene resulted in induction of
strong anti--galactosidase antibody responses (53). Here we
show that immunization of mice with KUN replicons express-
ing the murine polyepitope or polytope (Mpt) (50, 51) as a
model immunogen and delivered in the form of naked RNA,
VLPs, or plasmid DNA resulted in induction of CD8 T-cell
responses specific to encoded epitopes and protected mice
from viral and tumor challenges.
MATERIALS AND METHODS
Plasmids. RNA-based (RNALeu) and DNA-based (DNALeu) KUN replicon
vectors contain two copies of 2A autoprotease of the foot-and-mouth disease
virus (FMDV2A), one upstream and another downstream of the cloning site, as
well as leucine (Leu) at amino acid position 250 in the KUN NS1 gene product
(Fig. 1B). RNAPro and DNAPro vectors contain proline (Pro) instead of Leu at
amino acid position 250, and they were constructed by replacing the SphI-SphI
fragment spanning the entire NS1 gene in the RNALeu and DNALeu vectors
with the corresponding SphI-SphI fragment from the KUN full-length cDNA
plasmid 250pro (16). The Mpt sequence was PCR amplified from the plasmid
pSTMPDV (50) with primers Mpt-F (5-GCGACGCGTCTAGAGCCAGCAA
CGAGAA-3) and Mpt-R (5-GTAACGCGTCTAAGTCCTCGGGGCCGG-
3). The PCR product was then digested with MluI and cloned into the MluI site
of each of the four vectors, to produce plasmids RNALeuMpt, RNAProMpt,
DNALeuMpt, and DNAProMpt, respectively (Fig. 1B).
FIG. 1. Schematic representation of the replicon gene expression and delivery systems based on the KUN replicon (A) and of the KUN replicon
constructs encoding Mpt (B). (A) KUN replicon RNA can be transcribed in vitro from plasmid DNA incorporating the bacteriophage SP6
promoter and delivered as naked RNA via transfection or injection (25, 52). It can also be synthesized in vivo by cellular RNA polymerase II from
transfected or injected plasmid DNA incorporating the cytomegalovirus (CMV) promoter (53). In addition, KUN replicon RNA can be first
packaged into VLPs by using a packaging system described previously (27) and then delivered by infection (52). Regardless of the delivery mode,
once in the cytoplasm, KUN replicon RNA initiates self-replication, leading to production of multiple RNA copies, translation of which results
in enhanced production of encoded HG products. CAP represents the cap structure added to the 5 terminus of replicon RNA molecules either
synthetically during in vitro transcription or naturally during in vivo transcription or KUN RNA replication, to ensure efficient initiation of
translation. (B) KUN replicon constructs contain sequences required for KUN RNA replication, i.e., 5 and 3 UTRs; sequences coding for the
first 20 amino acids of the KUN C protein (C20) and the last 22 amino acids of the KUN E protein (E22); and the entire nonstructural region
coding for the KUN nonstructural proteins NS1 (shown as NS1) and NS2A, NS2B, NS3, NS4A, NS4B, and NS5 (shown as NS2-NS5). In addition,
constructs contain either SP6 or CMV promoters upstream of the KUN 5 UTR to drive in vitro or in vivo RNA transcription, respectively, and
the antigenomic sequence of the hepatitis delta virus ribozyme (HDVr) and the polyadenylation signal from simian virus 40 (pA) inserted
downstream of the 3 UTR to ensure production of KUN replicon RNA molecules with precise 3 termini for efficient initiation of replication. To
allow cytoplasmic release of Mpt peptide from the KUN C20 and E22 peptides, the constructs contain two copies of the 2A autoprotease of the
foot-and-mouth disease virus (FMDV2A), one upstream and another downstream of the Mpt sequence. Pro and Leu variants contain amino acid
Pro or Leu at position 250 in the KUN NS1 gene product, respectively.
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DNA and RNA transfections, IF, and Northern blot analyses. For DNA
transfections, BHK21 cells in six-well plates or on coverslips were transfected
with 2 or 0.4 g of plasmid DNAs, respectively, by using Lipofectamine Plus
transfection reagent (Life Technologies, Melbourne, Australia), as described by
the manufacturer. RNAs were transcribed in vitro by the SP6 RNA polymerase
from the XhoI-linearized RNA-based plasmid DNAs and electroporated into
BHK21 cells as described previously (25). Coverslips with transfected cells were
fixed in cold acetone at 48 h after transfections and assayed for expression of
KUN NS3 protein by indirect immunofluorescence (IF) with anti-NS3 antibodies
as described previously (56). Northern blot analysis of total RNA from trans-
fected cells was performed as described previously (25) using 32P-labeled cDNA
probes representing either the KUN 3 untranslated region (UTR) or the Mpt
sequence.
Preparation of VLPs. VLPs (VLPProMpt) were prepared as described previ-
ously (27, 52). Briefly, 2  106 BHK21 cells were electroporated with 10 to 20
g of in vitro-transcribed RNAProMpt RNA at 1.5 kV, 25 F, and  resistance,
with two pulses at a 10-s interval. After electroporation cells were diluted in 8 ml
of Dulbecco modified Eagle medium (DMEM)–10% fetal calf serum (FCS) and
cultured in 60-mm-diameter dishes at 37°C in a CO2 incubator. After 32 h cells
were trypsinized and used for a second electroporation with in vitro-transcribed
SFV replicon RNA expressing KUN structural proteins (SFV-MEC105) (27)
under the same conditions. At 18 h after the second electroporation, the medium
was replaced with 3 ml of DMEM–2% FCS, and cells were incubated for a
further 22 h. The medium was harvested and clarified by spinning at 8,000  g
prior to storage in 1-ml aliquots at 70°C. The titer of infectious VLPs was
determined by infecting BHK21 cells with 10-fold serial dilutions of the VLPs
and counting the number of NS3-positive cells after IF analysis at 30 to 40 h
postinfection.
Immunization of mice. Female BALB/c (H-2d) mice (6 to 8 weeks) were
supplied by the Animal Resources Centre (Perth, Western Australia, Australia).
Mice were immunized with the following formulations: (i) KUN replicon poly-
tope DNA plasmids, DNALeuMpt and DNAProMpt, encoding KUN replicons
expressing Mpt and injected into the quadriceps muscles (100 g in 100 l of
phosphate-buffered saline [PBS], intramuscularly [i.m.], 50 l into each leg); (ii)
in vitro-transcribed KUN replicon RNAs, RNALeuMpt and RNAProMpt, en-
coding Mpt, dissolved in diethyl pyrocarbonate-treated PBS and injected as
described above (30 g in 100 l, i.m., 50 l in each leg); (iii) replicon RNA
RNAProMPt packaged into VLPs (VLPProMpt) delivered in DMEM–2% FCS
and injected intraperitoneally (i.p.) (5  105 VLPs in 1 ml); (iv) a conventional
plasmid DNA vaccine, pSTMPDV, encoding Mpt (100 g in 100 l of PBS, i.m.,
50 l into each quadriceps muscle) (50); and (v) a recombinant vaccinia virus
encoding Mpt (107 PFU in 200 l of RPMI 1640, i.p.) as described previously
(51).
CD8 T-cell assays. Epitope-specific gamma interferon (IFN-	)-secreting
cells were enumerated by an enzyme-linked immunospot (ELISPOT) assay with
minimal CD8 T-cell peptide epitopes as described previously (30). Briefly,
flat-bottomed 96-well MultiScreen-HA cellulose ester membrane microtiter
plates (Millipore Australia Ltd., North Ryde, Australia) were coated overnight
with 5 g of rat anti-mouse IFN-	 antibody (clone RA-6A2; BD PharMingen,
San Diego, Calif.)/ml. Coated plates were then blocked with 1% bovine serum
albumin in PBS for 1 h at room temperature and washed three times with PBS
containing 0.05% Tween 20 (Sigma). Splenocytes (106/well) were plated in the
first wells of the ELISPOT plate and serially diluted twofold. Recombinant
human interleukin-2 (kindly provided by Cetus Corp., Emeryville, Calif.) (100
IU/ml) was added with peptide (Mimotopes, Clayton, Victoria, Australia) (1
g/ml), and the plates were incubated for 18 h. The cells were lysed, the plates
were washed, and IFN-	 spots were detected by incubation first with biotinylated
anti-mouse IFN-	 antibody (clone XMG 1.2) (BD PharMingen) and then with
streptavidin-alkaline phosphatase (BD PharMingen) and Sigma Fast 5-bromo-
4-chloro-3-indolylphosphate–nitroblue tetrazolium (BCIP-NBT) substrate (Sig-
ma). Spots were counted using a KS ELISPOT reader (Carl Zeiss Vision GmbH,
Hallbergmoos, Germany). The different immunization modalities were com-
pared using a two-way analysis of variance (ANOVA) with a model that con-
tained the modality and all the epitope responses and used a Tukey post hoc test
for multiple comparisons.
51Chromium (51Cr) release assays were performed as described previously (9).
Briefly, mice were sacrificed 2 to 3 weeks postimmunization with VLPProMpt,
and splenocytes were restimulated in vitro for 6 days by the addition of 1 g of
peptide (Mimotopes)/ml. The resulting effector populations were split, and equal
numbers were used in duplicate against peptide-sensitized and nonsensitized
51Cr-labeled P815 target cells at the indicated effector-to-target ratios.
Vaccinia virus protection assay. Groups (n 
 6) of 6- to 8-week-old female
BALB/c mice were immunized once with 30 g of RNALeuMpt or control
(RNALeuControl) RNAs and after 3 weeks challenged i.p. with 107 PFU of
recombinant vaccinia virus encoding Mpt (rVVMpt) (51) per mouse. At day 4
postinfection, both ovaries were removed, washed, and homogenized in 1 ml of
PBS with a motorized grinder. A 100-l quantity of ovary suspension was then
mixed with 900 l of PBS containing trypsin (Sigma) at 1 mg/ml and incubated
for 30 min at 37°C. The solution was briefly centrifuged at 10,000  g to remove
debris, and 100 l of the supernatant was mixed with 900 l of RPMI–10% FCS
medium. The vaccinia virus titers in ovaries were then determined by plaque
assay on confluent CV1 cells. The significance of the differences between the
virus titers in the experimental and control groups was calculated using the
Wilcoxon rank-sum test (7).
Tumor protection assay. B16 melanoma cells expressing ovalbumin (B16-
OVA) (3) were kindly supplied by K. Rock (Dana-Farber Cancer Institute,
Boston, Mass.). Groups of C57BL/6 mice (n 
 6) were vaccinated i.m. twice,
separated by 4 weeks, with 30 g of either RNALeuMpt or control RNALeu-
Control RNAs, or once with rVVMpt, and 2 weeks after the last immunization
mice were injected subcutaneously at two different sites on the back with B16-
OVA cells (105 cells per mouse). Hair around the injection site was removed with
an electric shaver prior to injection to facilitate measurement of the emerging
tumors. Growing tumors were monitored, and the animals were sacrificed when
tumor size reached 15 by 15 mm. Mean tumor area was calculated for each
treatment group at the indicated number of days after the tumor challenge. The
difference in the mean tumor growth between groups was calculated using
ANOVA (45). The time when animals were sacrificed was also noted and rep-
resented as Kaplan-Meier survival curves (31). Differences between Kaplan-
Meier survival curves were calculated using the log-rank statistic (31).
RESULTS
Efficient replication of KUN replicons encoding Mpt in
transfected cells. Plasmid DNAs DNALeuMpt and DNA
ProMpt encoding KUN replicon cDNAs expressing Mpt were
transfected into BHK21 cells, and replication and expression
of corresponding replicon RNAs transcribed in cells by RNA
polymerase II were examined by Northern blotting and IF
analyses. In vitro-synthesized Mpt-encoding KUN replicon
RNAs RNALeuMpt and RNAProMpt were transfected into
BHK21 cells by electroporation and analyzed for their repli-
cation and expression. IF analysis of transfected cells with
KUN anti-NS3 antibodies showed that 50% of cells were
positive after transfection with DNA-based replicons and
80% of cells were positive after electroporation with RNA-
based replicons (Fig. 2A). In our previous experiments with
electroporation of KUN replicon RNAs, expression of KUN
NS3 could be detected by IF only when these RNAs were
capable of replication (25, 26). Transfection of plasmid DNA
encoding KUN cDNA did, however, result in detection of
expression of KUN proteins by IF, even when the KUN RNA
was unable to replicate (29). To ensure that replicon RNAs
produced in cells from transfected plasmid DNAs DNA
LeuMpt and DNAProMpt were replicating, we analyzed total
cellular RNA by Northern blot analysis with a KUN-specific
radiolabeled cDNA probe (Fig. 2A). Comparison of the inten-
sity of the radioactive signal in these samples with that de-
tected in the RNA sample isolated from cells transfected with
the same amount of the control plasmid DNA pKUNrep2
(dGDD) producing replication-deficient KUN replicon RNA
(53) showed that 5- to 10-fold-higher amounts of KUN-
specific RNAs were produced in DNALeuMpt- and DNA
ProMpt-transfected cells than in pKUNrep2(dGDD)-trans-
fected cells. Previous studies with replication-competent and
replication-deficient KUN DNA-based replicon constructs
showed similar differences in the amounts of accumulated
RNAs (53). These results demonstrated that replicon RNAs
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produced in cells from the transfected plasmid DNAs DNA
LeuMpt and DNAProMpt were replication competent. North-
ern blot analysis with a KUN-specific cDNA probe of total
RNA isolated from cells electroporated with in vitro-synthe-
sized RNAs RNALeuMpt and RNAProMpt (Fig. 2B) con-
firmed the IF results (Fig. 2A), and together they demon-
strated efficient replication and accumulation of KUN replicon
RNA in transfected cells. Note that two times more total cel-
lular RNA was loaded on the gel for RNA-transfected samples
than for DNA-transfected samples (Fig. 2B) and also that
ethidium bromide staining of the gel showed a similar concen-
tration of rRNAs in corresponding (RNA-transfected or
DNA-transfected) samples (data not shown).
To examine whether the Mpt sequence was retained during
replication of replicon RNAs in cells, the membrane contain-
ing the same RNA samples (left panel in Fig. 2B) was reprobed
with a radiolabeled cDNA probe specific for the Mpt se-
quence. The results (right panel in Fig. 2B) were identical to
those obtained using the KUN-specific probe (left panel in Fig.
2B) and clearly demonstrated that the Mpt sequence was in-
deed retained during amplification of KUN replicon RNAs in
transfected cells.
The purpose of generating Leu- and Pro-containing con-
structs was to evaluate a possible effect of this mutation at
amino acid position 250 in the KUN NS1 gene product on the
replication and accumulation of KUN replicon RNA and thus
on the levels of expression of encoded HGs both in vitro and
in vivo. It was previously shown that a Pro (wild type)-to-Leu
mutation at amino acid 250 in the KUN NS1 gene product
resulted in the loss of dimerization of the NS1 protein. This
caused a delay in virus replication in Vero cells and attenua-
tion of virus replication in mice (16). Infection of Vero cells
with equal amounts of Leu- and Pro-containing viruses pro-
duced 100-fold less of the Leu-containing virus in the first
24 h, but similar yields of Leu- and Pro-containing viruses were
obtained by 48 h after infection. In in vivo experiments, 100-
FIG. 2. Evidence of replication of KUN replicon constructs encoding Mpt in transfected BHK21 cells. (A) IF analysis of BHK21 cells
transfected with DNA-based or RNA-based KUN replicons encoding Mpt. Cells on coverslips were transfected with KUN replicon-polytope DNAs
(DNALeuMpt and DNAProMpt) or RNAs (RNALeuMpt and RNAProMpt) and assayed for expression of KUN NS3 proteins by IF at 48 h after
transfection. (B) Northern blot of total RNA from BHK21 cells transfected with KUN replicon-polytope DNAs and RNAs. Transfection of cells,
RNA isolation, and Northern blotting were performed as described in Materials and Methods. The left panel shows results of Northern blotting
with a KUN-specific probe representing the KUN 3 UTR, and the right panel shows results of Northern blotting of the same membrane
rehybridized with the probe representing the Mpt sequence. Samples from DNA-transfected cells contain 6 g of total RNA, and samples from
RNA-transfected cells contain 12 g of total RNA. pKUNRep2(dGDD) lines show RNA samples isolated from BHK cells transfected with
pKUNRep2(dGDD) DNA producing nonreplicating KUN replicon RNA encoding -galactosidase (53). The position of this RNA in the left
panel is indicated by the asterisk. Control RNA represents 10 ng of in vitro-transcribed RNALeuMpt RNA.
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fold-more Leu-containing virus was required to generate sim-
ilar clinical symptoms of the disease in mice (16). In the
present study with KUN-Mpt replicon constructs, the amounts
of KUN RNA accumulated in BHK21 cells transfected with
DNA-based Leu- and Pro-containing replicon constructs were
similar (compare DNALeuMpt and DNAProMpt lanes in Fig.
2B), while transfections with in vitro-transcribed RNAs
showed slightly higher levels of RNA accumulation in cells
transfected with Leu-containing RNA than in cells transfected
with Pro-containing RNA (compare RNALeuMpt and RNA
ProMpt in Fig. 2B). As mentioned above, the amounts of
rRNAs were similar in corresponding samples as judged by
ethidium bromide staining. Transfection of RNALeuMpt
RNA also resulted in a slightly higher proportion of NS3-
positive cells in IF analysis (Fig. 2A). Noticeably, a significantly
higher number of rounded (dead) NS3-positive cells were seen
after transfection with RNAProMpt RNA than after transfec-
tion with RNALeuMpt RNA (Fig. 2A), suggesting higher cy-
topathicity of the former RNA. A similar difference in cytoto-
pathicity between Pro- and Leu-containing variants was also
observed following transfections of corresponding KUN repli-
con vector RNAs RNAPro and RNALeu (data not shown).
Induction of CD8 T-cell responses following immunization
with DNA-, RNA-, and VLP-based KUN replicons expressing a
polytope immunogen. The Mpt immunogen contains four con-
joined CD8 T-cell epitopes restricted by H-2d; these include
YPHFMPTNL (an H-2Ld-restricted epitope from murine cy-
tomegalovirus pp89), RPQASGVYM (H-2Ld-restricted epitope
from lymphocytic choriomeningitis virus nucleoprotein),
TYQRTRALV (H-2Kd epitope from influenza virus nucleo-
protein), and SYIPSAEKI (H-2Kd epitope from Plasmodium
berghei circumsporozoite protein). BALB/c mice were immu-
nized once with KUN replicon DNA, RNA, and VLPs encod-
ing the Mpt immunogen, and after 2 to 3 weeks CD8 T-cell
responses to each of the four CD8 T-cell peptide epitopes
were measured using IFN-	 ELISPOT (Fig. 3A). The ELIS-
POT responses generated by the RNA and VLP KUN vaccines
were comparable to those induced by a recombinant vaccinia
virus encoding the same polytope immunogen (rVVMpt) (Fig.
3A). ANOVA showed a P value of 0.34 for RNAProMpt ver-
sus rVVMpt immunizations and a P value of 1 for VLPProMpt
versus rVVMpt immunizations. A single immunization with
DNAProMpt or DNALeuMpt also induced responses compa-
rable with those reported for two immunizations with a con-
FIG. 3. Cytotoxic T-lymphocyte responses specific for YPHFMPTML (YPH), RPQASGVYM (RPQ), TYQRTRALV (TYQ), and SYIPSA
EKI (SYI) epitopes induced by immunization with various KUN replicon-based vectors encoding Mpt immunogen. (A) ELISPOT analysis of
BALB/c (n
 4 per group) mouse splenocytes following immunization with the indicated vaccines. (B) 51Cr release assay of restimulated splenocyte
populations from BALB/c mice (n 
 3 per group) immunized with VLPProMpt. A standard 6-h Cr release assay was performed using labeled
target cells sensitized with (filled squares) or not sensitized with (empty squares) the indicated peptides. SE, standard error.
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ventional DNA encoding the same immunogen (30, 50) (see
also Fig. 4). The hierarchy of epitope responses, with the RPQ-
specific responses dominating the YPH responses and the SYI
responses dominating the TYQ responses, has been observed
previously and is thought to reflect the lower major histocom-
patibility complex-binding affinity of the subdominant epitopes
(30). Although Pro-containing replicons appeared to be more
cytopathic than Leu-containing replicons in transfected
BHK21 cells (see above), no significant differences between
these variants were observed in induction of CD8 T-cell re-
sponses (Fig. 3A) (ANOVA, P 
 0.92 for RNAProMpt versus
RNALeuMpt, and P 
 0.39 for DNAProMpt versus DNA
LeuMpt) (see also Fig. 4).
Mice immunized once with VLPProMpt were also assayed
for the induction of cytotoxic CD8 T-cell responses by 51Cr
release assay. Significant cytotoxic activity specific for each
epitope was observed (Fig. 3B), although TYQ responses were
subdominant as shown previously (30, 50, 51). These responses
were again comparable with those observed previously for
mice immunized once with rVVMpt (51) and higher than those
seen previously for mice immunized twice with a conventional
DNA vaccine encoding the polytope immunogen (50).
Immunization of mice with 10-fold serial dilutions of the
DNA-based KUN-polytope replicons DNALeuMpt and DNA
ProMpt illustrated that CD8 T-cell responses were still de-
tectable after a single immunization with only 0.1 g of KUN
replicon DNA (Fig. 4). The magnitude of CD8 T-cell re-
sponses induced by 0.1 g of the KUN vaccine was comparable
to the magnitude of those induced by immunization with 100
g of conventional plasmid DNA-polytope vaccine (Fig. 4)
(Student’s t test results for DNALeuMpt and DNAProMpt [0.1
g] versus conventional DNA [100 g] were P
 0.34 and 0.55,
respectively). This number of CD8 T cells induced by 100 g
of KUN Mpt DNA was also approximately five to six times
higher than the number induced by 100 g of the conventional
plasmid DNA-polytope vaccine (Fig. 4) (Student’s t test results
for DNALeuMpt and DNAProMpt [100 g] versus conven-
tional DNA [100 g] were P  0.001 for both).
The data presented in this section illustrate that KUN rep-
licon-based vaccines, delivered by any of the three different
modalities (DNA, RNA, and VLPs), can efficiently induce
CD8 T cells, generating responses similar in magnitude to
those for recombinant vaccinia virus-based vectors and signif-
icantly higher than those for conventional DNA vaccines.
Naked RNA immunization with KUN replicon vectors en-
coding polytope protects mice from viral and tumor chal-
lenges. To determine whether the CD8 T-cell responses in-
duced by immunization with KUN replicon vectors could
protect against viral challenge, mice were vaccinated once with
RNALeuMpt RNA or RNALeuControl RNA (prepared from
the RNALeu vector DNA) and were then challenged with
rVVMpt. The rVVMpt challenge assay measured protection
mediated through all four H-2d-restricted epitopes presented
by the KUN vaccine. Following a single vaccination with
RNALeuMpt RNA, a significant (70%) reduction in ovary
rVV titers was observed (Fig. 5A; P 
 0.03). Comparable
protection was obtained using a conventional DNA-polytope
vaccine but only after two immunizations (50).
The Mpt sequence also encodes the ovalbumin-derived
CD8 T-cell epitope SIINFEKL (50, 51), permitting examina-
tion of tumor protection following KUN vaccination using
challenge with B16 tumor cells expressing ovalbumin (B16-
OVA). Mice were immunized twice with RNALeuMpt and
RNALeuControl or once with rVVMpt and then challenged
with B16-OVA. A significantly lower rate of tumor growth was
observed for RNALeuMpt-immunized mice than for RNALeu
Control-immunized animals (P  0.001) (Fig. 5B, upper graph).
Furthermore, the average rate of tumor growth in RNA
LeuMpt-immunized mice was also lower than that following
immunization with rVVMpt (P 
 0.001). The data from the
same experiment are also presented as Kaplan-Meier curves
(Fig. 5B, lower graph), which show the percentage of mice
surviving at the indicated time points. Again, RNALeuMpt-
immunized mice performed significantly better than RNALeu
Control-immunized animals (P 
 0.015) and than rVVMpt-
immunized animals (P 
 0.016).
DISCUSSION
We have demonstrated the ability of KUN replicon vectors
to induce CD8 T-cell responses to an encoded model im-
munogen after a single immunization. All three delivery mo-
dalities, i.e., naked RNA, plasmid DNA, and VLPs, efficiently
induced CD8 T-cell responses. Immunization with naked rep-
licon RNA also protected mice from virus and tumor chal-
lenges. These results demonstrate the potential of KUN repl-
icon-based vaccine vectors for the induction of protective
CD8 T-cell responses. The magnitude of CD8 T-cell re-
sponses obtained using KUN replicon vectors was comparable
to the magnitude of those obtained with recombinant vaccinia
FIG. 4. Cytotoxic T-lymphocyte responses specific for SYIPSAEKI
induced after immunization with different doses of DNA-based KUN
replicons encoding the Mpt. DNALeuMpt and DNAProMpt were
serially diluted in PBS, and the indicated doses were injected into
quadriceps muscles of BALB/c mice (n 
 4 per group). Mice were
sacrificed 2 weeks later, and cytotoxic T-lymphocyte responses were
measured by the ELISPOT assay. SE, standard error.
3796 ANRAKU ET AL. J. VIROL.
 o
n
 Septem
ber 15, 2016 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
virus, a vaccine vector modality widely regarded as an effective
vector for CD8 T-cell induction (44). A number of poxvirus
vaccine vectors are currently being tested for their ability to
induce protective CD8 T-cell responses in primates and hu-
mans; these include modified vaccinia virus Ankara (47), fowl-
pox virus (43), and canarypox virus (15).
Alphavirus replicons have been extensively used for the in-
duction of immune responses in animal models, and replicons
derived from VEE have recently been approved for preclinical
trials in humans (http://www.alphavax.com/pp_inhouse.html).
Similar to the alphavirus replicon systems, KUN replicons can
be delivered by three different modalities: as naked RNA, as
plasmid DNA, and as VLPs. In accordance with the results
obtained with alphavirus DNA-based replicons (4, 17), immu-
nization with only 0.1 g of KUN DNA-based replicon was
sufficient to elicit CD8 T-cell responses. A similar level of
CD8 T-cell induction was achieved only after immunization
with a 1,000-fold-higher dose (100 g) of a conventional plas-
mid DNA vaccine (Fig. 4).
Naked RNA immunization is becoming increasingly popular
for demonstrating the potential of replicon-based vectors to
induce protective antiviral and antitumor immune responses in
animal models (11, 55, 58). RNA immunization avoids issues
relating to DNA integration and may offer additional advan-
tages over immunization with VLPs. In contrast to naked
RNA, immunization with VLPs is likely to lead to the induc-
tion of neutralizing antibody responses to the structural pro-
teins of VLPs, a phenomenon which may limit the number of
times that the VLPs can be used in one individual. In contrast,
preexisting CD8 T cells specific for the vaccine vector or the
vaccine antigen do not normally appear to influence the effi-
ciency of induction of CD8 T-cell response to the vaccine
antigen following immunization (48). RNA-based vaccines are
also easier to manufacture than are VLPs. Recent reports also
suggest that RNA can be encapsulated into microparticles and
delivered into animals by bombardment with a gene gun (37,
54). Encapsulated RNA was also shown previously to be stable
for 8 to 12 months at 4°C (37). Previous studies with naked
RNA immunization of SIN and SFV replicon vaccines have
shown effective induction of antigen-specific antibody and
CD8 T-cell responses (11, 55, 58). Similarly, we have shown
that RNA immunization with KUN replicon vaccines resulted
in the induction of CD8 T-cell responses specific for an en-
coded immunogen with efficiency comparable to that obtained
after immunizations with DNA-based or VLP-based KUN rep-
licons (Fig. 3A). RNA vaccination using KUN or SIN replicons
also induced significant antitumor protection in different tu-
mor models (Fig. 5B) (58).
One particular feature of flaviviruses may prove to be ben-
eficial for the use of their replicons as safe vaccine vectors.
Flaviviruses, in general, have shown no evidence of recombi-
nation between different viruses or virus strains in nature. Our
previous numerous complementation experiments with defec-
tive full-length KUN RNAs and replicon RNA as a helper also
failed to show any evidence of recombination between these
two (full-length and replicon) RNAs coreplicating in the same
cell despite the presence of extended regions of perfect ho-
mology in both RNAs (summarized in reference 28). Also, no
recombinations leading to the recovery of recombinant viruses
were detected in complementation experiments with yellow
fever virus RNAs containing deletions in the NS1 gene when
the helper NS1 protein was supplied either from homologous
viruses (yellow fever virus) or from heterologous viruses (den-
gue virus) (34, 35). This feature of flaviviruses is in contrast to
the well-documented recombination abilities of alphavirus
RNAs (18, 42, 46) and may provide an extra level of safety for
vaccinations of individuals, who may be infected with the same
FIG. 5. Recombinant vaccinia virus and B16-OVA tumor challenge
following RNALeuMpt vaccination. (A) Recombinant vaccinia virus
challenge. BALB/c mice (n 
 6 per group) were vaccinated once with
RNALeuMpt or RNALeuControl RNAs and then challenged with
rVVMpt. Vaccinia virus titers in ovaries were measured at day 4 after
infection. (B) B16-OVA challenge. BALB/c mice (n 
 6 per group)
were immunized twice with either RNALeuControl or RNALeuMpt
RNAs or once with recombinant vaccinia virus encoding Mpt (rVVMpt)
and were then challenged with B16-OVA cells. The top graph shows
the average tumor area for 12 tumor sites for each of the three groups
of mice. The tumor growth lines stop on the date when the first tumor
in a group reached the size of 15 by 15 mm, requiring the animal’s
euthanatization. The bottom graph represents Kaplan-Meier survival
curves of the three groups of mice. Mice were euthanatized when the
tumor size reached 15 by 15 mm. SE, standard error.
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or other flaviviruses either just before or some time after im-
munization. In addition, the heterologous nature of the KUN
replicon packaging system, employing a replicon RNA-based
vector from a totally unrelated virus, SFV, for the expression of
KUN structural proteins, as well as the specific design of the
expression construct, makes KUN VLP preparations abso-
lutely safe and free of any infectious recombinant viral material
(27, 52).
Perhaps one of the most distinctive features of the KUN
replicons is that their replication does not cause an overt cy-
topathic effect or apoptosis (25, 52, 53). Cytopathic effect or
apoptosis of infected cells containing vaccine antigens was re-
ported elsewhere to be an efficient method for cross priming,
resulting in the delivery of vaccine antigens to dendritic cells
(DCs) and effective CD8 T-cell induction (2, 58). However,
despite exhibiting a very low or undetectable level of cytopath-
icity in vitro (Leu-containing variants [Fig. 2A]), KUN repli-
cons efficiently induced CD8 T-cell responses in mice (Fig. 3
and 4). Furthermore, no significant differences were observed
in the inductions of CD8 T-cell responses by the Leu- and
Pro-containing variants of the KUN replicon vectors (Fig. 3
and 4), which had shown different degrees of cytopathicity in
transfected BHK21 cells (Fig. 2A). CD8 T-cell induction by
KUN replicons may thus be independent of apoptosis-medi-
ated cross priming (5) and/or may not require cross priming. It
has been shown elsewhere that flaviviruses can directly infect,
replicate in, and activate DCs (19–21, 32, 57), suggesting that
KUN replicons may also be able to replicate and produce
vaccine antigens in DCs. Direct infection of DCs by vaccine
vectors may represent a more efficient strategy for CD8 T-cell
induction than cross priming (49). Lymphotropic VEE repli-
con particles as well as DC-adapted SIN replicon particles
were recently shown elsewhere to be able to infect DCs and
express an encoded vaccine antigen (14, 36). However, the
cytopathic nature of alphavirus replicon RNAs may lead to
apoptosis of antigen-presenting DCs and a reduction in CD8
T-cell activation or induction. In contrast, KUN replicons with
limited levels of cytopathicity may allow prolonged antigen
expression in DCs without causing apoptosis, a feature which
may contribute to prolonged stimulation of CD8 T-cell re-
sponses. Induction of tolerance is unlikely, due to the ever-
present double-stranded RNA, which is believed to induce
danger signals and activate DCs (13).
In summary, KUN replicons have been shown to be effective
vaccine vectors for the induction of protective CD8 T cells
and may represent an attractive new modality for cancer and
human immunodeficiency virus vaccines. We are currently ex-
ploring the ability of these persistent KUN vaccines to main-
tain long-term effector CD8 T-cell populations, a feature that
may be highly desirable for prophylactic human immunodefi-
ciency virus vaccines, as memory CD8 T-cell responses may
be insufficient to protect against challenge (23, 38).
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